Asthma and COPD in Older People

Vanessa Marie McDonald B. Nurs

A Thesis Submitted for the Degree of Doctor of Philosophy ~ Medicine August 2010

DECLARATION

This thesis contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying subject to the provisions of the Copyright Act 1968.

Date	Vanessa M McDonald

ACKNOWLEDGEMENT OF AUTHORSHIP

I hereby certify that the work embodied in paper/s/scholarly work of which I am a join thesis a written statement, endorsed by me the joint publication/s/scholarly work.	·
Statement of contribution for: Gibson PG Adults. <i>Lancet.</i> 2010: 374; 803-813.	, McDonald VM, Marks GB. Asthma in Older
Vanessa McDonald made a significant co this review article.	ntribution to the design and co-authorship of
Peter G Gibson	Vanessa M McDonald

ACKNOWLEDGEMENTS

It is a pleasure to thank the many people that have made this thesis possible and who have provided me with support over the last 4 years. Foremost I would like to recognise and express my sincere gratitude to my supervisors, Professors Peter Gibson and Isabel Higgins. Peter, for many years I have valued your mentorship, support and encouragement. I am grateful to you for suggesting to me that a PhD is achievable and for your guidance and the wisdom you have offered throughout my candidature. Isabel, you have been a wonderful support to me and I have learnt a great deal from you. Thank you for providing me with outstanding guidance and sharing your expertise. I feel privileged to have had the opportunity to complete my PhD under the supervision of you both.

I wish to acknowledge the funding support of the NHMRC Centre for Respiratory and Sleep Medicine, the Cooperative Research Centre for Asthma and Airways (CRCAA), the University of Newcastle Foundation and HMRI Barker Scholarship and the HMRI Greaves RHD Support Grant.

This thesis would not have been possible without the assistance and support of my many colleagues from the Asthma and Respiratory Disease Priority Research Centre. In particular, I would like to offer an enormous thanks to Kelly Steel and Rebecca Oldham for your involvement as clinical research officers in these studies. Also to Amber Smith for providing the dietary component of the IPBM study and Jo Smart for being so obliging when doing all the DEXA scans. You guys have been a delightful study team and I am grateful for your commitment and friendship. A massive thanks also goes to the laboratory processing team: Michelle Gleeson, Bridget Ridewood, Kellie Fakes and Naomi Fibbens for managing all the samples. I am grateful to Deborah Hall for keeping me organised, to Katie Baines for the pep talks and lovely friendship and to my 'RHD comrades' particularly Alan 'Alby' Hsu and Hayley See for their camaraderie. A special thankyou must be given to the wonderful Heather Powell for all the statistical advice provided. Heather you have been an absolute gem and fine teacher! I have learnt so much from you and value your knowledge and support.

I have been very fortunate to do my PhD in an outstanding research group and in doing so I have had the pleasure of developing collaborations with some fantastic people, in particular Dr Jodie Simpson and Dr Lisa Wood. I have valued the opportunities to work with you; your support, advice, enthusiasm, willingness to share your research experience and your friendship has been very special.

A clinical PhD would not happen without involvement from the patients who volunteer their time; my gratitude goes out to the 200 plus patients who have participated in the studies presented in this thesis. Recruiting these patients was made much easier by the support of my colleagues, the respiratory physicians, advanced trainees and the respiratory liaison team of the Department of Respiratory and Sleep Medicine. Thank you to all of you, especially Dr Keith Murree-Allen for the time you spent editing this thesis and Dr Nick Saltos for your constant support and encouragement. I would also like to recognise the continued support of my managers Professor Michael Hensley and Mrs Carmel Peek. I have been extremely fortunate to work for people who have valued my pursuit of higher education and who have continued to extend my leave requirements unfailingly.

To my besties; two very special and amazing women who have provided me with exceptional encouragement, support and love. To Naomi Fibbens and my lifelong friend Vicki Mansfield: thank you both for your unfaltering encouragement, words of wisdom and never ending laughs. I don't know what I would do without either of you! I feel truly blessed to have you both in my life!

To my parents, Bill and Chris Lewis, thank you for not only believing in me but for teaching me to believe that anything is possible. There have been many times when I questioned my ability to get this far but to you both those thoughts were an impossibility. Thank you for your love, help and the continual support that you both afford. I would also like to thank both my beautiful Bupcia, Maria Slusarski for always believing in me and Leonne McDonald for providing me with love, support, weekly school pick ups and gourmet dinners!

Finally, to one awesome young person, my beautiful baby girl Olivia McDonald. Sweetheart your kindness, maturity and perspective constantly amazes me. You have been more patient than any 11 year old should have to be and I owe my deepest gratitude to you for that. You are a wonderful daughter and the best little friend a Mum could ever hope for. Every day you make me incredibly proud, I love you [∞]. Finally it is over!

ABBREVIATIONS

AHR Airway Hyperresponsiveness

ASMM Appendicular Skeletal Muscle Mass

ASMMI Appendicular Skeletal Muscle Mass Index

ATS American Thoracic Society

Ax Assessment

BDR Bronchodilator Response

BMD Bone Mineral Density

BP Blood Pressure

BMI Body Mass Index

CCI Charlson Co-morbidity Index

CPG Clinical practice guidelines

COPD Chronic Obstructive Pulmonary Disease

DEXA Dual Energy X-Ray Absorptiometry

Dx Diagnosis

EA Eosinophilic Asthma

ELISA Enzyme Linked Immunosorbent Assay

FENO Fractional Exhaled Nitric Oxide

FER Forced Expiratory Ratio

FEV₁ Forced Expiratory Volume in 1 second

FVC Forced Vital Capacity

GINA Global Initiative for Asthma

GORD Gastro Oesophageal Reflux Disease

GP General Practitioner

HADS Hospital Anxiety and Depression Scale

HR Heart Rate

HR Max Maximum Heart Rate

HRQoL Health Related Quality of Life

hs-CRP high sensitivity C-Reactive Protein

ICS Inhaled Corticosteroids

IDP Inhaler device polypharmacy

IG Intervention group

IL Interleukin

IPBM Integrated Problem Based Management

IQR Interquartile range

LABA Long Acting Beta Agonist

LBP LPS Binding Protein

LLN Lower limit of normal

LTRA Leukotriene Receptor Antagonist

MDA Multidimensional assessment

mg Milligram

mL Millilitre

MMRC Modified Medical Research Council

ng nanogram

NT-Pro BNP N-Terminal Pro-B-Type Natriuretic Peptide

NA Neutrophilic Asthma

NE Neutrophil Elastase

NEA Non-eosinophilic Asthma

OAD Obstructive Airway Disease

VIII

OCS Oral Corticosteroids

PEF Peak Expiratory Flow

PCC Person Centred Care

PC20 Provocation concentration resulting in a 20% fall in FEV1

PD15 saline Provocation Dose of saline resulting in a fall in FEV1 of 15%

pg Picogram

PGA Paucigranulocytic Asthma

pMDI Pressurised Metered Dose Inhaler

PRP Pulmonary rehabilitation programme

RR Respiratory rate

SABA Short Acting Beta 2 Agonist

SAPS Short Assessment of Patient Satisfaction

SD Standard deviation

SGRQ Saint George Respiratory Questionnaire

SME Self-management Education

SpO2 Pulse Oximeter Oxygen Saturation

Sx Symptom

TNF-α Tumor Necrosis Factor-alpha

UC Usual care

ULN Upper limit of normal

WAP Written action plan

6 MWT Six Minute Walk Tests

PUBLICATIONS ARISING FROM THIS THESIS

Articles

- 1. Gibson PG, **McDonald VM**, Marks GB. Asthma in Older Adults. *Lancet*. 2010: 374; 803-813
- McDonald VM, Simpson JL, Higgins I, Gibson PG. Multidimensional
 Assessment of Older People with Asthma and COPD: clinical management issues and health status. Age and Ageing 2010:40;42-9
- 3. **McDonald VM**, Higgins I, Simpson JL, Gibson PG. The importance of clinical management problems in older people with COPD and asthma; do patients and physicians agree? *Prim Care Resp J* Accepted July 2010.
- McDonald VM, Gibson PG. Asthma mortality and management in older Australians: time for a new approach? *Australasian Journal on Ageing* Vol 27 No 4 December 2008, 215

Book Chapters

McDonald VM, Gibson PG. Patient Education, Asthma Self-management.
 In Allergy Frontiers: Diagnosis and Health Economics. Editors Pawankar R,
 Holgate S, Rosenwaser L. Springer Publishing 2009 978-4-431-98293

Abstracts

- McDonald VM, Higgins I, Wood LG, Gibson PG. Multidimensional Assessment and Individualised Management of Obstructive Airway Diseases (OAD) in Older Adults. Accepted as a "Late breaking" abstract European Respiratory Society, Barcelona Spain September 2010 (E1)
- Vanessa M McDonald, Jodie L Simpson, Isabel Higgins, Peter G Gibson Six minute walk tests: are practice tests necessary? Respirology (2010) 15, (4) A17 (E1)

- Vanessa M McDonald, Jodie L Simpson, Isabel Higgins, Peter G Gibson. Is there an association between self reported activity limitation and exercise tolerance in COPD? Respirology (2010) 15, (4) A59 (E1)
- 4. Jodie L Simpson, **Vanessa M McDonald**, Peter G Gibson. The relationship between systemic inflammation, airway inflammation and airway obstruction in COPD. Respirology (2010) 15, (4) A33 (E1)
- Jodie L Simpson, Vanessa M McDonald, Peter G Gibson. Exhaled nitric oxide is not a marker of eosinophilic inflammation in older Australians. Respirology (2010) 15, (4) A53 (E1)
- Joanne Smart, Peter A Wark, Vanessa M McDonald, Lisa G Wood. CRP, body composition and lung function in ex-smokers. Respirology (2010) 15, (4) A57 (E1)
- VM McDonald, P McElduff, JL Simpson, I Higgins, PG Gibson
 Multidimensional clinical problem assessment in asthma and COPD: Patient
 Physician concordance. Respirology (2009) 14, (Suppl. 1) A19 (E1)
- VM McDonald, LG Wood, J Smart, I Higgins, PG Gibson. Does sarcopenic obesity exist in older people with COPD? Respirology (2009) 14, (Suppl. 1) A52 (E1)
- VM McDonald, LG Wood, J Smart, I Higgins, PG Gibson. An Investigation of Sarcopenic Obesity in COPD. (2009) Am J Respir Crit Care Med 179;2009:A4039 (E1)
- 10. VM McDonald, P McElduff, JL Simpson, I Higgins, PG Gibson, Multidimensional problem assessment of asthma and COPD in an older population: Patient Physician concordance. (2009) Eur Resp J, (Suppl.) (E1)
- 11. JL Simpson, PM. Hansbro, VM McDonald, PG Gibson. Age and Disease Related Changes in Airway Inflammation in Older People with COPD. Respirology (2008) 10, (Suppl.) A25 (E1)
- McDonald VM, Simpson JL, Higgins I, Gibson PG. A Problem Based Assessment of Asthma and COPD in Older People. Respirology (2008) 10, (Suppl.) A25) (E1)

- 13. **McDonald VM**, Higgins I, Gibson PG. The Use of Qualitative Interviews to Gain Insight into Older People with COPD and Asthma. Respirology (2008) *10*, (Suppl.) A25) (E1)
- 14. JL Simpson, P Hansbro, VM McDonald and PG Gibson. Age and disease related changes in airway inflammation and inflammatory subtype in older people with COPD. Am J Respir Crit Care Med; 2008; 177:A874 (E1)
- 15. **McDonald VM,** Simpson JS, Higgins I, Gibson PG. A problem based assessment of obstructive airways disease (OAD) in an elderly population. European Respiratory Society, Stockholm Sweden 2007 (E1)

TABLE OF CONTENTS

DECLARATION	II
ACKNOWLEDGEMENT OF AUTHORSHIP	III
ACKNOWLEDGEMENTS	IV
ABBREVIATIONS	VII
PUBLICATIONS ARISING FROM THIS THESIS	X
TABLE OF CONTENTS	XIII
TABLE OF TABLES	XVI
TABLES OF FIGURES	XVIII
Abstract	XX
Synopsis	XXI
CHAPTER 1 BACKGROUND AND INTRODUCTION	1 -
1.1 ASTHMA	
1.1.1 DEFINITION AND DISEASE BURDEN	
1.1.2 DIAGNOSIS	
1.2 COPD	
1.2.1 DEFINITION AND DISEASE BURDEN	
1.2.2 DIAGNOSIS	
1.2.3 MANAGEMENT	
1.3 AGE RELATED ISSUES	
1.3.1 AGEING POPULATION	14 -
1.3.2 AGEING AND THE LUNG	15 -
1.4 OBSTRUCTIVE AIRWAY DISEASE OVERLAP	19 -
1.4.1 DEFINITION AND PREVALENCE	
1.4.2 HETEROGENEITY OF AIRWAY INFLAMMATION	
1.5 MULTI-SYSTEM MULTI-COMPONENT DISEASE	
1.5.1 CO-MORBIDITY	
1.5.1 ADDITIONAL CLINICAL PROBLEMS	
1.6 SELF-MANAGEMENT	
1.7 CURRENT MANAGEMENT AND GUIDELINE GAP - OVERLAP OAD	
1.8 CHRONIC DISEASE MANAGEMENT	
1.9 PERSON CENTRED CARE (PCC)	
1.10 PATIENT EXPERIENCE	
1.11 STATEMENT OF THE PROBLEM, AIMS OF THE STUDY AND RESEARCH QUESTIONS RESEARCH QUESTIONS	
1 12 MIXED METHODS APPROACH	

CHAPTER Z	WETHODS	04 -
2.1 Еті	HICAL CONSIDERATIONS	65 -
2.1.1	PARTICIPANT SAFETY	66 -
2.2 DA	TA MANAGEMENT	- 68 -
	ATISTICAL ANALYSIS	
	EMATIC ANALYSIS	
	SESSMENTS	
	QUESTIONNAIRES	
2.5.1		
2.5.2	CLINICAL ASSESSMENTS	
2.5.3	LABORATORY BIOMARKERS	85 -
CHAPTER 3	CHARACTERISATION OF OAD IN OLDER PEOPLE	89 -
3.1.1	Introduction	90 -
3.1.2	DESIGN AND STUDY PARTICIPANTS	91 -
3.1.3	METHOD	91 -
3.1.4	Analysis	
3.1.5	Results	
3.1.6	DISCUSSION	
3.1.7	Conclusions	
3.1.7	CONCLUSIONS	124 -
CHAPTER 4		
PEOPLE'S EXF	PERIENCE OF COPD AND ASTHMA	126 -
4.1.1	INTRODUCTION	127 -
4.1.2	DESIGN AND METHOD	128 -
4.1.3	Analysis	130 -
4.1.4	DESCRIPTION OF PARTICIPANTS	
4.1.5	Results	
4.1.6	DISCUSSION	
4.1.7	Conclusions	
4.1.7	CONCLUSIONS	100 -
CHAPTER 5	PHYSICIAN – PATIENT CONCORDANCE	167 -
5.1.1	Introduction	
5.1.2	DESIGN, METHOD AND PARTICIPANTS	170 -
5.1.3	RESULTS	
5.1.4	DISCUSSION	
5.1.5	Conclusions	
CHAPTER 6	INTEGRATED PROBLEM BASED MANAGEMENT (IPBM) ~ A PILOT	STUDY- 182 -
6.1.1	Introduction	_ 183 _
6.1.2	STUDY DESIGN, METHOD AND PARTICIPANTS	
6.1.3	RESULTS	
6.1.4	DISCUSSION	
6.1.5	Conclusions	236 -
CHAPTER 7	DISCUSSION, CONCLUSIONS AND FUTURE DIRECTIONS	239 -
7.1 Su	MMARY	240 -
7.2 Eur	TUDE DIDECTIONS	247

APPENDICES - 249 -

ASSESSMENT OF INHALED RESPIRATORY MEDICATION DEVICES TECHNIQUES	250 -
INFORMATION AND CONSENT: CHAPTER 3, 4 AND 5	252 -
CASE RECORD FILE: CHAPTER 3 AND CHAPTER 5	261 -
INFORMATION AND CONSENT: CHAPTER 6	291 -
CASE RECORD FILE -CHAPTER 6	298 -
WRITTEN ACTION PLAN USED IN CHAPTER 6	329 -
STRENGTH TRAINING HOME PROGRAMME USED IN CHAPTER 6 [450]	330 -

REFERENCES - 332 -

TABLE OF TABLES

TABLE 1-1 CURRENT PREVALENCE OF PROBABLE ASTHMA, BY AGE GROUP AND SEX, ALL AGES, AUSTRALIA, 2004–05. REPRODUCED FROM [6] 3 -
TABLE 1-2 GOLD SPIROMETRIC CLASSIFICATION OF COPD SEVERITY BASED ON POST
BRONCHODILATOR FEV $_1$ [30]11
TABLE 1-3 COPD MANAGEMENT ACCORDING TO DISEASE SEVERITY 12 -
Table 1-4 Types and causes of airway inflammation in OAD. Reproduced from [84]24
TABLE 1-5 CLINICAL MANAGEMENT ISSUES AND CONCORDANCE WITH GUIDELINES 47
TABLE 1-6 TERMINOLOGY AND APPROACHES USED IN CHRONIC DISEASE MANAGEMENT - 51 -
TABLE 1-7 MIXED METHODS PROCEDURES 62 -
TABLE 2-1 CALCULATION OF BODE INDEX. REPRODUCED FROM [132] 75
Table 2-2 Medications withheld including times for a hypertonic saline challenge 85
TABLE 2-3 CYTOSPIN QUALITY SCORE
TABLE 3-1 MULTIDIMENSIONAL ASSESSMENT TO DETECT CLINICAL MANAGEMENT ISSUES- 93
TABLE 3-2 PARTICIPANT CHARACTERISTICS BY DIAGNOSIS 98
TABLE 3-3 PREVALENCE OF CURRENT AND SIGNIFICANT CO-MORBIDITIES 99
TABLE 3-4 CLINICAL MANAGEMENT PROBLEMS DETECTED USING THE MDA 102
TABLE 3-5 CLINICAL PROBLEMS BY DIAGNOSIS 104 -
TABLE 3-6 LINEAR REGRESSION MODEL DEMONSTRATING THE RELATIONSHIP BETWEEN
SGRQ AND THE NUMBER OF CLINICAL PROBLEMS 111 -
TABLE 3-7 RELATIONSHIP BETWEEN BODE AND AIRWAY AND SYSTEMIC INFLAMMATION AND CLINICAL OUTCOMES 114 -
TABLE 3-8 SIMPLE LINEAR REGRESSION EXAMINING THE RELATIONSHIP BETWEEN BODE AND SGRQ 114
TABLE 3-9 BIOMARKER AND CLINICAL ASSESSMENTS BY DIAGNOSIS 115 -
Table 3-10 Relationship between Neutrophilic Airway Inflammation and Systemic Inflammation and Clinical Outcomes 117
TABLE 3-11 RELATIONSHIP BETWEEN EOSINOPHILIC AIRWAY INFLAMMATION AND SYSTEMIC INFLAMMATION AND CLINICAL OUTCOMES 117 -
TABLE 3-12 SPUTUM MICROBIOLOGY 117 -
TABLE 3-13 LOGISTIC REGRESSION EXAMINING THE RELATIONSHIP BETWEEN PATHOGEN
COLONISATION AND AIRWAY INFLAMMATION 118
TABLE 3-14 TWO BY TWO TABLE DEMONSTRATING THE PROPORTION OF PARTICIPANTS WITH
THE COEXISTENCE OF ACTIVITY LIMITATION AND EXERCISE INTOLERANCE 119
TABLE 3-15 SIMPLE AND MULTIPLE LOGISTIC REGRESSION MODELS EXAMINING THE RELATIONSHIP BETWEEN ACTIVITY LIMITATION AND INDEPENDENT VARIABLES
TABLE 4-1 PARTICIPANT CHARACTERISTICS 131 - 132 - 132 - 132 - 132 - 133 - 134 - 135 - 13
TABLE 5-1 DESCRIPTIONS OF CLINICAL PROBLEMS AS PRESENTED TO THE PHYSICIAN AND PARTICIPANT
TABLE 5-2 PARTICIPANT CHARACTERISTICS 173
TABLE 5-3 THE MOST PREVALENT CLINICAL PROBLEMS IDENTIFIED BY THE MDA 173 -

TABLE 5-4 CONCORDANCE OF PROBLEMS RATED AS MOST IMPORTANT BY BOTH THE PATIENT AND THE PHYSICIAN	- 174 -
TABLE 6-1 MULTIDIMENSIONAL ASSESSMENT USED IN IPBM	- 187 -
Table 6-2 Pulmonary Rehabilitation Education Sessions	- 188 -
TABLE 6-3 THE PREDEFINED NUMBER OF VISITS REQUIRED TO ADDRESS THE CLINICAL MANAGEMENT PROBLEMS	- 190 -
TABLE 6-4 ALGORITHM FOR ANTIBIOTIC PRESCRIPTION ON THE WRITTEN ACTION PLAN	- 194 -
Table 6-5 Inflammation based Algorithm	- 197 -
Table 6-6 Algorithm for the treatment of eosinophilic bronchitis. (Adapte FROM [82])	
Table 6-7 Baseline Participant Characteristics	- 213 -
TABLE 6-8 MEDICATION PRESCRIBED AT STUDY ENTRY	- 214 -
Table 6-9 Clinical Management Issues Identified through the MDA	- 215 -
TABLE 6-10 INTERVENTIONS DELIVERED TO THE IG	- 216 -
Table 6-11 Clinical Management Issues Identified through the MDA pre and ntervention (IG only)	
TABLE 6-12 BIOMARKERS OF INFLAMMATION IN THE GROUP RECEIVING TREATMENT TAILORED TO INFLAMMATION USING THE INFLAMMATION TREATMENT ALGORITHM	- 219 -
Table 6-13 IG biomarkers pre and post intervention	- 229 -
Table 6-14 Number of exacerbations experienced within the treatment perifor the IG and UC group	

TABLES OF FIGURES

FIGURE 1-1 GLOBAL INITIATIVE FOR ASTHMA (GINA) ASTHMA MANAGEMENT APPROACH BASED ON CONTROL. REPRODUCED FROM [1]	_
FIGURE 1-2 CHANGING AGE STRUCTURE OF THE AUSTRALIAN POPULATION, 1925-2045.	
REPRODUCED FROM [59]15	-
FIGURE 1-3 AGE-RELATED DECLINE IN FEV1 BY STRATA IN MALES DERIVED FROM LINEAR MIXED EFFECTS MODELS. MEAN FEV1 IN MILLILITRES (CORRECTED FOR HEIGHT, WEIGHT, AND AGE AT FIRST SURVEY) FOR AGES 18 TO 80 YEARS FOR MALES: (REPRODUCED FROM [62])	_
FIGURE 1-4 COPD AND AGEING-RELATED CHANGES TO PHYSIOLOGIC, ANATOMIC, AND IMMUNOLOGIC PARAMETERS. REPRODUCED FROM [68]	
FIGURE 1-5 NONPROPORTIONAL VENN DIAGRAM PRODUCED BY THE ATS OF COPD SHOWING SUBSETS OF PATIENTS WITH CHRONIC BRONCHITIS, EMPHYSEMA, AND ASTHMA. SPECIFIC DISEASE SUBSETS ARE LABELLED 1-11	_
FIGURE 1-6 COPD AS A MULTI-COMPONENT DISEASE. REPRODUCED FROM [88] 26	-
FIGURE 1-7 COMPONENTS OF OAD IN OLDER ADULTS AND TREATMENT INTERVENTIONS [84]	
FIGURE 1-8 THE SYSTEMIC EFFECTS AND CO-MORBIDITIES OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) HAVE 3 POSSIBLE EXPLANATIONS 29	
Figure 1-9 Visual Model of the Concurrent Triangulation Mixed Method Design 62 -	-
FIGURE 3-1 CHARLSON CO-MORBIDITY INDEX SCORE BY DIAGNOSIS 99	-
FIGURE 3-2 MANAGEMENT ISSUES IDENTIFIED BY MULTIDIMENSIONAL ASSESSMENT, PRESENTED BY DOMAIN: A) PATHOPHYSIOLOGY; B) SYMPTOMS; C) DISEASE MANAGEMENT SKILLS 100	_
FIGURE 3-3 BMI CLASSIFICATION OF THE PARTICIPANTS 103	
FIGURE 3-4 CLINICAL MANAGEMENT ISSUES ACCORDING TO DIAGNOSIS. THE NUMBER OF CLINICAL MANAGEMENT ISSUES WAS SIMILAR IRRESPECTIVE OF THE DIAGNOSIS 105	-
FIGURE 3-5 PRE BRONCHODILATOR FEV ₁ % OF PREDICTED BY DIAGNOSIS 105	-
FIGURE 3-6 BMI (KG/M ²) BY DIAGNOSIS. VALUES >25KG/M ² INDICATE OVERWEIGHT AND >30KG/M ² INDICATE OBESITY	-
FIGURE 3-7 6 MINUTE WALK DISTANCE BY DIAGNOSIS. VALUES <350M INDICATE EXERCISE INTOLERANCE 107	
FIGURE 3-8 NUMBER OF CO-MORBIDITIES BY DIAGNOSIS 107	
FIGURE 3-9 CRP MG/ML BY DIAGNOSIS 108	-
FIGURE 3-10 SPUTUM NEUTROPHILS (%) BY DIAGNOSIS 109	
FIGURE 3-11 SPUTUM EOSINOPHILS (%) BY DIAGNOSIS 109	
FIGURE 3-12 HEALTH STATUS MEASURED BY SGRQ BY DIAGNOSIS 110	
FIGURE 3-13 HEALTH RELATED QUALITY OF LIFE IMPAIRMENT WAS ASSOCIATED WITH THE NUMBER OF MANAGEMENT PROBLEMS IDENTIFIED BY THE MULTIDIMENSIONAL ASSESSMENT 110 -	-
FIGURE 3-14 FEV1 WAS INVERSELY CORRELATED WITH THE NUMBER OF CLINICAL	
MANAGEMENT PROBLEMS IDENTIFIED USING THE MULTIDIMENSIONAL ASSESSMENT 111	-
FIGURE 3-15 AGE WAS NOT CORRELATED WITH THE NUMBER OF CLINICAL MANAGEMENT PROBLEMS IDENTIFIED USING THE MULTIDIMENSIONAL ASSESSMENT 112	-
FIGURE 3-16 AGE WAS NOT CORRELATED WITH THE TOTAL SGRQ SCORE 113	-

FIGURE 3-17 BODE INDEX BY DIAGNOSIS 113 -
FIGURE 3-18 AIRWAY INFLAMMATION SUBTYPES 116 -
FIGURE 3-19 PROBLEMS IDENTIFIED AND REPORTED AS THE MOST SIGNIFICANT BY THE PATIENT 118 -
FIGURE 4-1 INTERVIEW QUESTION GUIDE 129 -
FIGURE 5-1 PROBLEMS OF HIGH IMPORTANCE WHERE DISCORDANCE OCCURRED 175 -
FIGURE 5-2 PROBLEMS OF LESS IMPORTANCE WHERE CONCORDANCE WAS PRESENT 176 -
FIGURE 5-3 CONCORDANCE BETWEEN PATIENT AND PHYSICIAN OF PROBLEM IMPORTANCE RATING 177 -
FIGURE 6-1 CONSORT DIAGRAM OF PARTICIPANTS 211 -
FIGURE 6-2 SGRQ SCORE PRE AND POST INTERVENTION FOR THE IG AND UC 225 -
Figure 6-3 the mean pre and post difference in SGRQ score between groups 226 -
FIGURE 6-4 PRE AND POST SGRQ SCORES FOR THE IG AND UC 226 -
FIGURE 6-5 THE NUMBER OF CLINICAL PROBLEMS PRE AND POST INTERVENTION 227 -
FIGURE 6-6 HS-CRP PRE AND POST INTERVENTION FOR THE IG AND UC GROUP 230 -
FIGURE 7-1 SCHEMA OF THE BODY OF RESEARCH PRESENTED IN THIS THESIS 242 -
FIGURE 7-2 MODEL OF DISEASE MANAGEMENT FOR OLDER PEOPLE WITH OAD 246 -

ABSTRACT

Obstructive Airway Diseases (OAD) such as asthma and Chronic Obstructive Pulmonary Disease (COPD) are common conditions among older people where they are associated with a significant and increasing disease burden. The management of these conditions in older people is complex. The complexities relate to the heterogeneity that exists in asthma and COPD in the older population, the increased prevalence of co-morbidity that occurs with both advancing age and OAD, and the consequences of ageing including age related structural changes that occur in the lung. The current approach to the management of older people with asthma or COPD is to establish a diagnosis and implement disease specific clinical practice guidelines. This approach however is limited as the clinical trials that inform guidelines have largely excluded older people and those with overlap OAD or co-morbidity. A further restriction of this approach is that many of the guidelines for asthma and COPD give limited consideration to the consequences of ageing or the existence of multiple complex co-morbidities and do not necessarily address what is important to the patient. Opportunities exist to improve the management and outcomes for older people with OAD and the research undertaken in this thesis sought to do this.

The research reported in this thesis aimed to improve our current understanding of Asthma, COPD and the overlap of asthma and COPD in an older population, and to develop an improved approach to the management of these patients. A mixed methods approach was used involving a cross sectional observation study, qualitative interviews and a controlled clinical trial.

This research has extended our knowledge of the clinical impacts of these conditions from a biological, clinical, functional and person centred perspective and describes a management approach that significantly improves the health status of older people with OAD.

SYNOPSIS

Background

Obstructive Airway Diseases (OAD) such as asthma and Chronic Obstructive Pulmonary Disease (COPD) are common conditions among older people where they are associated with a significant and increasing disease burden. The management of these conditions in older people is complex. The complexities relate to the heterogeneity that exists in asthma and COPD in the older population, the increased prevalence of co-morbidity that occurs with both advancing age and OAD, and the consequences of ageing including age related structural changes that occur in the lung. The current approach to the management of older people with asthma or COPD is to establish a diagnosis and implement disease specific clinical practice guidelines. This approach however is limited as the clinical trials that inform guidelines have largely excluded older people and those with overlap OAD or co-morbidity. A further restriction of this approach is that many of the guidelines for asthma and COPD give limited consideration to the consequences of ageing or the existence of multiple complex co-morbidities and do not necessarily address what is important to the patient. Opportunities exist to improve the management and outcomes for older people with OAD and the research undertaken in this thesis sought to do this.

Aims:

The overall aims of this research were firstly to develop and test a multidimensional assessment to characterise asthma, COPD and overlap OAD in people over the age of 55 years from a functional, clinical, biological, behavioural and person centred perspective and to determine whether these characteristics differed according to the OAD diagnosis. I also aimed to gain a deeper understanding of the experiences of older people with OAD and to assess the level of concordance between patients and physicians in terms of the importance of disease management problems. The final aim was to design and test the feasibility of a novel model of disease management that included multidimensional assessment and individualised problem based management.

Design

A mixed methods design was employed that incorporated a cross sectional analytical study, qualitative interviews and a controlled clinical trial. In the cross sectional study

100 participants who were over the age of 55 years with stable OAD defined by a FEV₁ <80% of predicted and FER of <0.7 were recruited. Participants underwent a multidimensional assessment to characterise the clinical problems that exist in older people with OAD and to determine the differences and similarities of these problems between asthma, COPD and overlap OAD diagnoses. A subgroup of 52 participants and 4 physicians rated the importance of each of the clinical management problems detected using a 5 point Likert scale to determine concordance between patients and physicians about the importance of these problems. Qualitative interviews were conducted with 21 participants recruited to the cross sectional study to provide insight into the experiences of older people with OAD. These data were used to design an intervention of integrated problem based management (IPBM) and this intervention was tested in a controlled clinical trial involving 24 participants.

Results

The multidimensional assessment identified a mean (SD) of 11.3 (2.5) clinical management problems and 3.1 (1.8) co-morbid conditions per participant. Common problems were: airways hyperresponsiveness (80%); airway inflammation (74%); activity limitation (74%) and systemic inflammation (60.5%). The number and type of problems were similar irrespective of a diagnosis of asthma, COPD or overlap OAD (p=0.2). The degree of health status impairment correlated significantly with the number of clinical management problems detected (r = 0.59; p<0.000), and each additional problem contributed to a clinically significant (4.2 unit) decline in health status.

When participants and physicians were asked to rate the importance of the clinical problems that were detected, the highest rated problem by the patient was dyspnea, mean (SD) 4.7 (0.42), whereas inadequate inhaler technique was rated as most important by the physician, 4.5 (0.58). There was good participant - physician concordance for the problems of dyspnea 100%, activity limitation 89%, and airway inflammation 76%. Poor concordance was found for inhaler technique inadequacy 58%, inhaler device polypharmacy 33%, atopy 22%, airway hyperresponsiveness 10% and the absence of a written action plan 27%.

The qualitative interviews explored the experiences and needs of 21 older people with OAD. From the data, six themes emerged, including 'being with or without a diagnosis', 'limits to being', 'not being heard or recognised', 'expectation, fears and hopes', 'to medicate or not: the underuse, abuse and misuse' and 'needing to understand'. These themes highlighted the needs, wants, fears, and concerns of older people with OAD and the gaps in current management approaches from the patients' perspective. Of particular importance was the older person's desire for an approach that valued them. They pointed to the need for a timely diagnosis, information and better understanding and education about their disease and, better approaches to ongoing assessment of their disease including the desire for objective feedback on their disease progress.

A model of disease management was developed and was informed by the results of the earlier studies. There were 24 participants recruited to this trial, 12 were assigned to the intervention group (IG) which involved a multidimensional assessment and tailored problem based management and 12 were assigned to usual care. This intervention was tested in a pilot controlled clinical trial of 24 participants. Of the 24 participants 54% were female. The mean (SD) age was 70.6 (7.4) years and post b-d FEV₁ was 48.29% (20.86). In the IG, 66.6% received tailored therapy [steroids and/or macrolides] to normalise sputum cell counts, 50% received statins for systemic inflammation, 66% were treated for mucus hypersecretion and 33% for sleep disorders. The intervention resulted in significant improvements in quality of life (QOL): the mean (SD) pre Saint George Respiratory Questionnaire (SGRQ) score for the IG was 54.1 (11.6) versus post 41.7 (15.3), p=0.03 compared to 51.3 (12.9) versus 48.9 (12.8), p=0.6 for usual care. The mean (SD) improvement in SGRQ for the IG was -12.3 (12.5) versus -2.2 (8.3), p=0.04 for usual care.

Conclusions

This research has advanced our knowledge of older people with asthma and COPD. It demonstrated that older people with OAD experience multiple clinical issues that adversely impact their health status. The number and type are similar irrespective of diagnosis. The multidimensional assessment developed in this thesis identifies significant clinical issues that may not be addressed in a diagnosis centred approach suggesting that a multidimensional approach is necessary when assessing and

managing older people with OAD. In terms of the importance of managing these clinical problems discordance exists between participants and physicians. Furthermore older people with OAD desire more involvement in their disease management and want more information about and objective feedback.

A model of disease management that includes multidimensional assessment and individualised treatment tailored to the results of the MDA is feasible and results in clinically and statistically significant improvements in quality of life in older adults with asthma and COPD